Go Pro
NASDAQ:SLGL

Sol-Gel Technologies Q4 2024 Earnings Report

Sol-Gel Technologies logo
$72.00 -1.00 (-1.37%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$71.90 -0.11 (-0.15%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sol-Gel Technologies EPS Results

Actual EPS
-$3.20
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Sol-Gel Technologies Revenue Results

Actual Revenue
$1.03 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sol-Gel Technologies Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Sol-Gel Technologies' Q3 2026 earnings is estimated for Thursday, November 19, 2026, based on past reporting schedules

Earnings Documents

Sol-Gel Technologies Earnings Headlines

Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
See More Sol-Gel Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sol-Gel Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sol-Gel Technologies and other key companies, straight to your email.

About Sol-Gel Technologies

Sol-Gel Technologies (NASDAQ:SLGL) is an Israeli specialty pharmaceutical company focused on developing topical dermatological treatments. The company uses proprietary microencapsulation technology designed to improve the delivery, stability, and tolerability of active pharmaceutical ingredients applied to the skin.

Sol-Gel’s products include TWYNEO Cream, a topical combination of tretinoin and benzoyl peroxide for acne, and EPSOLAY Cream, a microencapsulated benzoyl peroxide treatment for inflammatory lesions associated with rosacea. Both products have received approval from the U.S. Food and Drug Administration and are commercialized in the United States through a licensing arrangement with Galderma.

Founded in 1997 and headquartered in Ness Ziona, Israel, Sol-Gel Technologies serves the dermatology market primarily through partnerships supporting the development and commercialization of its prescription products. The company also continues to develop additional topical treatments using its proprietary drug-delivery platform.

View Sol-Gel Technologies Profile